Lexeo Therapeutics in the NEWS
On July 15, 2024, Lexeo Therapeutics (LXEO) announced positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the Weill Cornell Medicine investigator-initiated Phase 1A trial (
This content is for paid subscribers.
Today’s Highlights
July 16, 2024
Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Today’s Highlights July 16, 2024
